Targeting the FABP1-PLG-PLAT axis inhibits fatty acid metabolic reprogramming and tumor angiogenesis by inhibiting fatty acid binding protein 1 (FABP1) and its downstream plasminogen (PLG) - tissue plasminogen activator (PLAT) signaling pathway. Here, PLG is linked to neoplasm.